Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 4/20 | 0.61 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977295 | 0.88 | MLYCD (0.66) | MLYCDHSD17B3ALOX5 | |
| SCHEMBL2990795 | 0.85 | MLYCD (0.63) | MLYCDHSD17B3ALOX5 | |
| SCHEMBL2985736 | 0.84 | MLYCD (0.72) | MLYCDHSD17B3ALOX5 | |
| SCHEMBL2990450 | 0.82 | MLYCD (0.67) | MLYCDHSD17B3ALOX5AR | |
| SCHEMBL2991731 | 0.82 | MLYCD (0.69) | MLYCDHSD17B3ALOX5 | |
| SCHEMBL2985671 | 0.80 | MLYCD (0.69) | MLYCDHSD17B3ALOX5AR | |
| SCHEMBL2984094 | 0.79 | MLYCD (0.69) | MLYCDHSD17B3ALOX5 | |
| SCHEMBL2986051 | 0.79 | MLYCD (0.64) | MLYCDHSD17B3ALOX5 | |
| SCHEMBL2991945 | 0.79 | MLYCD (0.69) | MLYCDHSD17B3ALOX5 | |
| SCHEMBL2988694 | 0.78 | MLYCD (0.71) | MLYCDHSD17B3ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | GAREAU YVES | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | LTC4S, LTA4H, CYSLTR1 | MLYCD 2142/4885HSD17B3 1193/4885ALOX5 17/4885 |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | LTC4S, LTA4H, LTB4R2 | MLYCD 2597/4885HSD17B3 1607/4885ALOX5 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.